Early detection of cancer in dogs and cats

Pet Type
Cat, Dog
Topic Area
Cancer
Content
Download/Print

Many dogs and cats develop cancer during their lifetime. The proportion of cancer as a cause of death is also high.

The lifetime risk of developing cancer is approximately 25–33% in dogs (1 in 4 to 1 in 3 animals) and approximately 20% in cats (1 in 5 animals) (https://www.akc.org/expert-advice/health/cancer-in-dogs/). The proportion of cancer-related deaths is estimated at 27–34% in dogs and 32–35% in cats of all causes of death (https://pmc.ncbi.nlm.nih.gov/articles/PMC11025767/). Significant breed-related differences are to be expected, especially in dogs. For cats, studies primarily involve older and geriatric animals, so the information on lifetime risk and the proportion of cancer-related deaths is likely somewhat overestimated (https://oncodaily.com/oncolibrary/cancer-in-cats).

In human medicine, a four times higher survival rate has been proven with early detection. Specifically, blood tests represent a promising solution for the early detection of cancer. In veterinary medicine, however, an improvement in survival time with early detection has not yet been clearly scientifically proven.

 

What methods of early cancer detection are available for dogs and cats?

Regular clinical examination for screening

A regular, annual clinical examination is recommended for all dogs and cats. This should be done annually for younger animals, up to about 7 years of age. In older dogs, very large breeds, and particularly at-risk breeds, semi-annual to annual clinical examinations, including laboratory tests (complete blood count, blood chemistry, urine) and blood pressure measurement, are recommended from 6 to 7 years of age. These systematic check-ups can serve for the early detection of clinically silent neoplasms (e.g., subcutaneous nodules).

The following should be assessed:

  • Skin/subcutaneous tissue
  • Peripheral lymph nodes
  • Assessment of the oral cavity
  • Rectal examination dog (perianal, prostate)
  • Palpation of the Abdomen
  • Palpation of the skin and mammary glands

A fine-needle aspiration (FNA) of any palpable mass is the most effective early detection of solid Tumors on the body surface.

 

Imaging as a screening aid

Thorax / chest X-ray and Abdomen ultrasound are useful “according to the findings,” i.e., if there are suspicious findings, e.g., in the case of unclear laboratory and clinical findings. A general annual X-ray examination of the thorax / chest or a general ultrasound examination of the abdominal and pelvic region are not recommended (https://pubmed.ncbi.nlm.nih.gov/36584321/).

 

Laboratory diagnostics as a screening aid

  • Basic laboratory values (complete blood count, blood chemistry, urine)

Abnormalities such as unexpected anemia, thrombocytopenia, hypercalcemia, hyperglobulinemia, Hematuria, etc. can provide early indications of possible cancer and should always be cause for further investigation (https://pubmed.ncbi.nlm.nih.gov/36584321/).

  • FeLV/FIV tests (cats)

These tests indirectly serve early detection, as there are a number of FeLV-associated neoplasms. Regular testing is recommended for risk groups. (Life stage guidelines, https://pubmed.ncbi.nlm.nih.gov/33627003/).

  • BRAF test (dog, non-invasive, molecular genetic urine test)

This test is not indicated annually, but is urgently indicated if there is a suspicion of urothelial carcinoma (UC, transitional cell carcinoma, urothelial carcinoma of the bladder, urethra, and prostate). Suspicious signs are urinary symptoms such as Urinary urgency (pollakiuria) and Blut im Harn (Hämaturie). This test should also be used if imaging accessibility is poor. The test has high reliability (high specificity, good sensitivity) with a detection rate of approximately 85–95%. It is also suitable for monitoring the course of the disease. https://www.antechdiagnostics.com/test/cadet-braf/

Blood-based multi-cancer tests (dog), “Liquid Biopsy”

  • Multi-cancer tests are novel tests that can detect multiple types of cancer in the blood based on various biomarkers released by cancer cells. They enable cancer diagnostics at a very early stage. However, the reliability of positive and negative findings varies.
  • The tumor DNA test “OncoK9,” a multi-cancer test for dogs, has unfortunately no longer been available since 2024. Studies showed high specificity (approx. 98%) and moderate overall sensitivity (approx. 55–62%) across many tumor types. There was a high detection rate for systemic, usually particularly aggressive Tumors such as lymphoma, hemangiosarcoma, and osteosarcoma. Localized, solid Tumors were less well detected. The test was particularly useful for use in at-risk patients (age, breed, pre-existing conditions) as a supplement to clinical examination, FNA and imaging.
  • Nucleosome/epigenetics tests (Nu.Q Vet) in dogs are also blood tests for detecting systemic cancers. The manufacturers state a specificity of approximately 97%, although this test is also expected to have higher sensitivity for systemic Tumors (lymphoma, hemangiosarcoma) and lower sensitivity for localized solid Tumors. The test is not tumor-specific. Inflammatory conditions can lead to false positive results. The use of this test is useful as an additional screening in seniors and at-risk breeds, although positive results always require imaging and/or Zytologie confirmation (https://volition.com/nu-q-vet/).

Even though blood tests (Liquid Biopsy) for early cancer diagnosis in dogs are promising, a cautious routine application is currently recommended due to the still insufficient, reliable data on patient outcome. Appropriate consultation and decision-making with the pet owner is necessary (https://www.veterinarypracticenews.com/cancer-diagnostics-evidence/).

Practical tips

  • What tumor-specific early detection is available?

  1. Mammary Tumors (dog/cat)
  2. Palpation is the most effective “early detection” for mammary Tumors and the best Prophylaxe is early Ovariohysterektomie (dog). This significantly reduces the risk of mammary Tumors (generally accepted evidence; in senior guidelines as part of the medical history/prevention) (https://pubmed.ncbi.nlm.nih.gov/36584321/).
  3. Tumors of the oral cavity (cat, squamous cell carcinoma)
  4. A regular examination of the oral cavity in connection with professional dental care in dogs and cats is the basis. This allows the most common solid Tumors in cats to be detected at the earliest stage. (Life stage/senior guidelines, https://pubmed.ncbi.nlm.nih.gov/33627003/).

  • What is (not yet) proven

  1. General abdominal ultrasound screenings to detect hemangiosarcomas in order to prevent Emergencies caused by hemangiosarcoma ruptures are not sensitive to small Lesions and do not provide a proven benefit as a broad prevention program. This means that targeted ultrasound examinations are useful, but an annual routine screening is not recommended.
  2. Population-wide “cancer blood screening” (every senior, every year) currently has no guideline recommendation. It is used individually, risk-adjusted and only as a supplement to classic prevention (https://www.aaha.org/resources/2023-aaha-senior-care-guidelines-for-dogs-and-cats/).

  • At-risk patient

Check-ups should be carried out annually up to a middle age (7–8 years), and semi-annually–annually in older animals. A check-up includes: Anamnese (previous report), clinical examination, including skin, lymph nodes, oral cavity and rectal examination (dog), complete blood count, clinical chemistry, urine examination and blood pressure. Everything Palpable is punctured (FNA). Imaging is performed depending on the indication (https://www.aaha.org/resources/2023-aaha-senior-care-guidelines-for-dogs-and-cats/).

 

  1. Urinary symptoms → consider urine-BRAF. If the findings are positive → imaging + Zytologie or Biopsie (https://www.antechdiagnostics.com/test/cadet-braf/).
  2. Senior dog, special breeds, special critical medical history → Liquid Biopsy as an additional option (clarification regarding sensitivity, specificity and, if positive → targeted imaging, Feinnadelaspiration and Biopsie necessary) (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0266623).

 

  • Cat

  1. The FeLV/FIV status should be kept up to date, as a number of Tumors are indirectly associated with FeLV or FIV.
  2. A consistent oral cavity inspection during (annual) dental Prophylaxe contributes significantly to the early detection of squamous cell carcinoma of the oral cavity, the most common malignant Tumor in cats (https://pubmed.ncbi.nlm.nih.gov/33627003/).

 

Conclusion

  • The gold standard of early cancer detection remains the consistent annual check-up in dogs and cats up to middle age or the semi-annual clinical check-up in at-risk patients. In the event of unclear and/or suspicious findings, FNA or Biopsie and targeted imaging should follow immediately.
  • Liquid Biopsy tests in dogs are promising additions with high specificity, but limited in overall sensitivity, mainly in local Tumors, and are therefore not yet a substitute for classic diagnostics. Use should be selective and after informing the owners.